{"url_path":"/sec/imux/8-k/2026-08-11/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1280776/0001193805-26-001071-index.html","accession_number":"0001193805-26-001071","cik":"0001280776","ticker":"IMUX","issuer_name":"IMMUNIC, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1280776/0001193805-26-001071-index.html","primary_entity_key":"0001280776","primary_entity_name":"IMMUNIC, INC."},"word_count":154,"has_tables":true,"body_markdown":"** **\n\n \n\n  \n\n \n\n**Item 2.02. Results of Operations and Financial Condition**\n\n \n\nOn August 11, 2026, Immunic, Inc. (the “Company”)\nissued a press release, a copy of which is furnished herewith as Exhibit 99.1, announcing the Company’s financial results for the\nquarter ended June 30, 2026, and providing a corporate update (the “Earnings Release”).\n\n \n\nThe information contained in Item 2.02 of this Current\nReport on Form 8-K, including the Earnings Release, shall not be deemed “filed” for the purposes of Section 18 of the Securities\nExchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section or Sections 11\nand 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). In addition, this information shall not be\ndeemed incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission (the “Commission”),\nexcept as shall be expressly set forth by specific reference in any such filing."}